Login
$VXRT
$0.32 +$0.00 (0.0%) Close

$VXRT 8-K SEC Filings

Filed On Filing
05 Nov 2026 8-K: Results of Operations and Financial Condition

Topline data from 400-person sentinel safety cohort and approximately 5,000 patients in main cohort Phase 2b COVID-19 trial anticipated by mid-year 2027

19 Oct 2026 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

Board-certified surgeon and former Director of the Defense Health Agency brings extensive leadership, public health and governance experience

14 Sep 2026 8-K: Other Events

On September 3, 2026, the Board of Directors (the “Board”) of Vaxart, Inc. (the “Company”), approved a Director Resignation Policy that requires a director, following certification of the stockholder vote from the meeting at which the el...

25 Aug 2026 8-K: Other Events

On August 21, 2026, the Board of Directors (the “Board”) of Vaxart, Inc. (the “Company”), upon the recommendation of the Nominating and Governance Committee, formed two new committees of the Board: the Clinical and Regulatory Affairs Com...

06 Aug 2026 8-K: Results of Operations and Financial Condition

Reported topline data from 400-person sentinel cohort of the Phase 2b COVID-19 trial; Topline data from 400-person sentinel safety cohort and approximately 5,000 participants in main cohort anticipated in first half of 2027

28 Jul 2026 8-K: Other Events

On July 27, 2026, upon the recommendation of the Nominating and Governance Committee, the Board of Directors of Vaxart, Inc. (the “Board”) approved the reorganization of its Nominating and Governance Committee and the Compensation Commit...

17 Jul 2026 8-K: Submission of Matters to a Vote of Security Holders; Regulation FD Disclosure

SOUTH SAN FRANCISCO, Calif., July 17, 2026 -- Vaxart, Inc. (Nasdaq: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform...

07 Jul 2026 8-K: Other Events

Vaxart Reports Topline 12-Month Safety Data From the 400-Participant Sentinel Safety Cohort of the Phase 2b Clinical Trial of Its Oral Pill COVID-19 Vaccine

02 Jul 2026 8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure

This COOPERATION AGREEMENT (this “Agreement”) is made and entered into as of July 1, 2026, by and among Vaxart, Inc., a Delaware corporation (the “Company”), on the one hand, and Daniel P. Houle, a citizen of the United States, Mark Silv...

26 Jun 2026 8-K: Entry into a Material Definitive Agreement; Other Events

Latest Modification is Important Required Step to Releasing 12-month Data from 400-participant Sentinel Cohort

19 May 2026 8-K: Other Events

Company is Entering a Pivotal Phase to Demonstrate Value of its Unique Oral Vaccine Platform

07 May 2026 8-K: Results of Operations and Financial Condition

Topline data from 400-person sentinel cohort of the Phase 2b COVID-19 trial anticipated in Q2 2026

23 Apr 2026 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

Appointment strengthens Board’s clinical development and regulatory expertise as Vaxart advances its oral vaccine platform

21 Apr 2026 8-K: Other Events

On April 20, 2026, Vaxart, Inc. (the “Company”) entered into an amendment (the “Amendment”) to its lease agreement (the “Utah Avenue Lease”) with a landlord (the “Utah Avenue Landlord”) relating to certain properties currently leased to ...

17 Apr 2026 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more

PURCHASE AGREEMENT (the “Agreement”), dated as of April 16, 2026, by and between VAXART, INC., a Delaware corporation (the “Company”), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (the “Investor”).

12 Mar 2026 8-K: Results of Operations and Financial Condition

Topline data from 400-person sentinel cohort of the Phase 2b COVID-19 trial anticipated early Q2 2026

29 Dec 2025 8-K: Termination of a Material Definitive Agreement

On December 18, 2025, Vaxart, Inc., a Delaware corporation (the “Company”), entered into a termination agreement (the “Termination Agreement”) with Britannia Pointe Grand Limited Partnership, a Delaware limited partnership (the “Landlord...

13 Nov 2025 8-K: Results of Operations and Financial Condition

Entered into an exclusive license agreement with Dynavax for the Company’s COVID-19 oral pill vaccine candidate for potential cumulative proceeds of up to $700 million plus royalties

05 Nov 2025 8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure

Collaboration positioned to leverage Vaxart’s oral vaccine platform and Dynavax’s commercial experience to address the long-term need for easily administered COVID-19 vaccine options

10 Oct 2025 8-K: Regulation FD Disclosure

As previously disclosed, on August 5, 2025, Vaxart, Inc. (the “Company”) received written notification (the “Previous Notice”) in the form of a stop work order, directing the Company to stop work on all of the Company’s efforts with resp...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support